Together with the analysis of p53 staining versus the presence of pathogenic TP53 mutations (Fig. 5), these examples illustrate how somatic tumour features from other platforms can be combined with in situ TIME estimates in breast cancer to add nuance to analyses and explore novel hypotheses. This evidence concerns the gene TP53 and breast cancer.